Chief scientist of ACTL targeted anti-tumor immune technology. Graduated from Zhejiang Medical University with a doctorate degree. In 1998, he went to the United States and received funding from the National Natural Science Foundation of China, the Natural Science Foundation of Zhejiang Province, the National Institutes of Health (NIH), the American National and Arkansas Cancer Society and other scientific research projects.
self introduction:
Under the tutelage of Paul Hermonat, an international authority in the field of adeno-associated viruses, and the 2011 Nobel laureate Ralph Steinman
Served as Deputy Director of the Gene and Biotherapy Center of the Rockefeller Cancer Center at the University of Arkansas School of Medicine
Served as Deputy Director of the Immunotherapy Center of the Cancer Center of Stanford Bridge University School of Medicine (in preparation)
PhD, Zhejiang Medical University
Postdoctoral fellow, Arkansas Medical University, Assistant Professor, Associate Professor, Professor, Clinical Lecturer
U.S. and Hong Kong medical oncologist license
Inventor of ACTL Technology, Chief Scientist of ISKCON
Distinguished, visiting or honorary professors from universities, research institutions and hospitals in China, Hong Kong, Japan, etc.
Member of the Oncology Biology and Immunotherapy Committee of the American Society of Clinical Oncology (ASCO)
Editors or full-time reviewers of several international basic and clinical journals related to tumors, immunity, viruses, and molecular biology
Major achievements:
Professor Liu Yong is the first to prove that the non-pathogenic Recombinant Adeno-associated Virus (rAAV) can effectively infect human dendritic cells, overturning the previous belief that Adeno-associated Virus (AAV) The view that it cannot be infected or the infection efficiency is extremely low. In the study, it was proved that rAAV-infected dendritic cells can effectively induce cytotoxic T lymphocytes with powerful targeted killing of malignant tumor cells. Subsequently, related clinical trials and research were carried out and succeeded. On this basis, an anti-tumor targeted cellular immunotherapy technology based on recombinant adeno-associated virus (AAV-DC-CTL, ACTL) was established. The clinical application of ACTL technology has achieved satisfactory results. The scientific research team led by Professor Liu Yong promoted the AAV vector from the third generation to the current eighth generation vector within a few years. The prepared rAAV virus not only has high titer, strong activity and high purity, but also fully meets the needs of clinical treatment. Moreover, the ACTL technology has been advanced from the first generation to the fourth generation, and the fifth and sixth generation ACTL technologies are under development. Over the past ten years, a total of more than 60 academic papers have been published, and several awards issued by the US NIH, ASCO, and the Cancer Society have been awarded. It has 5 US and international patents, 8 Chinese patent authorizations and more than 10 international and The Chinese patent is pending. The established Shenzhen Yishi Kangning Biotechnology Co., Ltd. has successively obtained Shenzhen High-tech Enterprise, National High-tech Enterprise, Shenzhen Science and Technology Progress Award, International Biotechnology Achievement Gold Award, and ISO9001 3 quality management system certifications within 4 years, and has obtained several government Funded R&D projects. In 2016, it was approved by the National Health and Family Planning Commission and was the first to carry out formal Phase II/III clinical trials for non-small cell lung adenocarcinoma and prostate cancer. The first large-scale targeted cellular immunotherapy clinical trial approved by this country not only provides clinical big data for precision medicine, but also puts my country at the international leading level in related fields.
main honor:
High-end foreign expert of China State Administration of Foreign Experts Affairs in 2011
2011 Beijing-Tianjin-Hebei high-tech leading talent
Talents of Tianjin "Thousand Talents Plan" in 2010
2013 Guangdong Science and Technology Leading Talent
2014 Shenzhen high-tech leading talent
2015 Talents of Hebei Province "Hundred Talents Program"
2016 Jiangsu 321 Engineering Talent
